US Consumer Health Industry In 2023: Mandatory Listing Has Supplement Sector’s Attention
Executive Summary
Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight reports here on whether support will emerge in Congress for FDA to gain MPL authority for all supplements sold in US.
You may also be interested in...
US FDA Narrows Guidance For New Dietary Ingredient Notifications To Magnify Compliance
Draft guidances in 2011 and 2016 were met with widespread questions and opposition from supplement industry, joined by then-senators who had were chief authors of DSHEA. FDA in 2023 said it would provide separate guidance documents on “discrete sections” of the requirement.
Tianeptine Rings Latest Unapproved Drug Alarm, Followed By Echo About Lack Of FDA Regulation
Tianeptine isn’t approved as drug in US nor allowed for use as dietary ingredient or food additive. FDA has warned multiple firms selling tianeptine-containing products and federal prosecutors recently announced guilty plea from man who sold the drug to consumers.
‘Lack Of Understanding’ Here, Spiked Product There Add Up To US Supplement Industry Image Problem
Research suggesting FDA more stringently regulate claims for fish oil supplements impresses industry as another sign the agency’s regulation and the requirements fulfilled by compliant businesses aren’t appreciated or understood. FDA announcement of ED drugs in products labeled as supplements shows agency must be aware students are starting or returning to classes.